BioPharma Resources

Drug Trial Radar · NCT07857733

Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1

An Open-Label, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous AMBTX-01 (Neridronate) for the Treatment of Complex Regional Pain Syndrome Type 1

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Dec 31, 2028

Study completion Feb 15, 2029

Sponsor

Lead sponsor
Ambros Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Conditions

  • Complex Regional Pain Syndrome Type I

Interventions

  • NeridronateDrug

    100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs), Acute Phase Reaction (APRs) and Treatment Emergent Serious Adverse Events (TESAEs) and Suspected Unexpected Serious Adverse Events (SUSARs) during the Open Label Extension Study.Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ambros Clinical Study Site

    Phoenix, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.